Originally published In Press as doi:10.1074/jbc.M202918200 on July 11, 2002
J. Biol. Chem., Vol. 277, Issue 42, 39074-39081, October 18, 2002
Discriminating between the Activities of Human Neutrophil
Elastase and Proteinase 3 Using Serpin-derived Fluorogenic
Substrates*
Brice
Korkmaz,
Sylvie
Attucci,
Eric
Hazouard,
Martine
Ferrandière,
Marie Lise
Jourdan
,
Michèle
Brillard-Bourdet,
Luiz
Juliano§, and
Francis
Gauthier¶
From the INSERM EMI-U 0010, Protéases et
Vectorisation, and
INSERM EMI-U 0211 University
François Rabelais, 2bis Boulevard Tonnellé, 37032 Tours
Cedex, France and § Departamento de Biofísica,
Escola Paulista de Medicina, Universidade Federal de São Paulo,
Rua Três de Maio, 100, São Paulo 04044-020, Brazil
Received for publication, March 26, 2002, and in revised form, June 19, 2002
 |
ABSTRACT |
Human neutrophil elastase (HNE) has long
been linked to the pathology of a variety of inflammatory diseases and
therefore is a potential target for therapeutic intervention. At least
two other serine proteases, proteinase 3 (Pr3) and cathepsin G, are stored within the same neutrophil primary granules as HNE and are
released from the cell at the same time at inflammatory sites. HNE and
Pr3 are structurally and functionally very similar, and no substrate is
currently available that is preferentially cleaved by Pr3 rather than
HNE. Discrimination between these two proteases is the first step in
elucidating their relative contributions to the development and spread
of inflammatory diseases. Therefore, we have prepared new fluorescent
peptidyl substrates derived from natural target proteins of the serpin
family. This was done because serpins are rapidly cleaved within their
reactive site loop whether they act as protease substrates or
inhibitors. The hydrolysis of peptide substrates reflects the
specificity of the parent serpin including those from
-1-protease
inhibitor and monocyte neutrophil elastase inhibitor, two potent
inhibitors of elastase and Pr3. More specific substrates for these
proteases were derived from the reactive site loop of plasminogen
activator inhibitor 1, proteinase inhibitors 6 and 9, and from the
related viral cytokine response modifier A (CrmA). This improved
specificity was obtained by using a cysteinyl residue at P1 for Pr3 and
an Ile residue for HNE and because of occupation of protease S'
subsites. These substrates enabled us to quantify nanomolar
concentrations of HNE and Pr3 that were free in solution or bound at
the neutrophil surface. As membrane-bound proteases resist inhibition
by endogenous inhibitors, measuring their activity at the surface of
neutrophils may be a great help in understanding their role during inflammation.
 |
INTRODUCTION |
Human neutrophil elastase
(HNE)1 and proteinase 3 (Pr3)
are very closely related serine proteases that are stored in
millimolar amounts within the primary granules of polymorphonuclear
neutrophils (PMN) (1-3). The activation and degranulation of PMNs at
an inflammatory site result in these proteases being translocated to
the surface of the plasma membrane and/or released from the PMN (2, 4). Thus, they are involved in the proteolytic events associated with inflammation such as the lysis of extracellular matrix components, the
control of cytokine activity, availability (5), platelet activation,
and blood coagulation (6, 7).
The contributions of HNE and Pr3 to the development of inflammatory
diseases remain to be elucidated, mainly because they have very similar
substrate specificities (1). Indeed, all of the synthetic substrates
for Pr3 assayed to date are hydrolyzed faster by HNE (8, 9) so that it
is virtually impossible to distinguish between the activities of these
two proteases when they are both present in a biological fluid.
However, Pr3 has some features that can help to distinguish it from
HNE. It is not inhibited by secretory leukocyte protease inhibitor,
which strongly inhibits HNE and cathepsin G, mainly in the upper
airways. Unlike HNE, Pr3 resists inhibition by DNA released from
pathogens and dead neutrophils (10). Pr3 also activates the
proinflammatory cytokines TNF-
and IL-1
(11, 12) and is the
target of autoantibodies in Wegener granulomatosis (13).
Because HNE and Pr3 have a site of interaction with their substrates
that extends on both sides of the sensitive bond (14), one way to
develop specific substrates for these proteases is to investigate their
P'specificity. This can be done using substrates with intramolecularly
quenched fluorescence that are cleaved within their amino acid sequence
(15). We have previously shown that sensitive intramolecularly quenched
fluorescent substrates of cathepsin G can be developed from the
sequence of the reactive site loop (RSL) of serpin inhibitors (16). An
initial substrate-like cleavage of the RSL occurs in serpins when they
interact with their target protease. This results in the irreversible
binding of the protease (inhibitory pathway) or in the inactivation of the serpin when the protease escapes from the complex (substrate pathway). In the latter case, the protease causes local depletion of
the inhibitor and takes part in the protease-protease inhibitor imbalance, especially at inflammatory sites. However, the RSL is always
cleaved, suggesting that RSL sequences can be used to develop
substrates for proteases that are not necessarily inhibited by the
corresponding serpin. We have prepared a series of synthetic fluorogenic peptides with intramolecularly quenched fluorescence based
on the exposed RSL of lung serpins that are putative target for
neutrophil neutral proteases, and we have used them as substrates for
HNE and Pr3. This study was done to identify substrates for specifically measuring HNE and Pr3 activities at the surface of neutrophils where bound proteases resist inhibition by local
inhibitors, thus favoring the development of inflammation.
The nomenclature used for the individual amino acid residues
(e.g. P1, P2, and so on) of a substrate and
corresponding residues of the enzyme subsites (e.g. S1, S2,
and so on) is that of Schechter and Berger (17).
 |
EXPERIMENTAL PROCEDURES |
Materials--
Human neutrophil elastase (EC 3.4.21.37),
proteinase 3 (EC 3.4.21.76),
1-antichymotrypsin, and
1-PI were
obtained from Athens Research and Technology (Athens, Georgia). Human
cathepsin G (EC 3.4.21.20) was from ICN Pharmaceuticals.
MeO-Suc-AAPV-pNA and Igepal CA-630 were from Sigma.
MeO-Suc-AAPV-AFC, Z-GLF-CMK, and MeO-Suc-AAPA-CMK were from Enzyme
System Products (Livermore, CA).
N,N-Dimethylformamide and acetonitrile were from
Merck; C18 cartridges for reverse-phase chromatography were from
Touzart et Matignon (Paris, France) and Interchim (Montluçon,
France). PolymorphprepTM and LymphoprepTM were
from Nycomed Pharma (Oslo, Norway). Monoclonal mouse IgG1-FITC and
CD63-FITC antibodies were from Beckman Coulter France (Roissy, France).
All other reagents were of analytical grade.
Isolation of Blood PMN--
Human neutrophils were purified from
8-ml samples of peripheral blood collected from volunteers into tubes
containing EDTA. Aliquots (4 ml) of blood were layered over 4-ml
Polymorphprep and centrifuged at 2,000 × g for 20 min
at 20 °C. The neutrophil-enriched bands (75% PMNs and 25%
lymphocytes) were harvested, diluted with an equal volume of
half-strength PBS, and brought to 6 ml with PBS. These samples were
layered over 3-ml Lymphoprep and centrifuged at 1,000 × g for 20 min at 20 °C. All of the resulting fractions with the exception of the neutrophil band at the bottom of the gradient
were carefully removed. Any erythrocytes remaining in the neutrophil
fraction were removed by hypotonic lysis. Purified PMNs were pelleted
at 500 × g for 5 min, and contaminating erythrocyte membranes were removed. The PMNs were suspended in PBS at
~3.103 cells/µl and used immediately or kept at
4-6 °C under gentle stirring.
Flow cytometry was performed on a Coulter Epics Elite ESP flow
cytometer equipped with a 488-nm argon laser. The forward and side
scatters of each sample were measured for at least 10,000 events.
Samples contained >99% neutrophils, no monocytes, and <1%
lymphocytes. CD63 surface expression was measured incubating 5 × 105 PMN with 20 µl of monoclonal IgG1-FITC or
CD63-phycoerythrin antibodies for 20 min in the dark and at room
temperature. The mixture was centrifuged at 500 × g
for 5 min, and the pellet washed twice in PBS and then resuspended in
PBS for flow cytometry.
Design and Synthesis of Quenched Fluorescent Substrates--
All
quenched fluorogenic substrates were prepared by solid-phase synthesis
with the Fmoc (N-(9-fluorenyl)methoxycarbonyl) methodology
using a multiple automated peptide synthesizer (PSSM-8, Shimadzu) (15,
18, 19). Glutamine was the C-terminal residue in all of the peptides
because of a requirement of the synthesis strategy (19). Substrate
purity was checked by matrix-assisted laser desorption ionization
time-of-flight mass spectrometry (TofSpec-E, Micromass) and by
reverse-phase chromatography on a C18 column eluted at 2 ml/min with a
10-min linear gradient of acetonitrile (0-60%) in 0.075%
trifluoroacetic acid. Stock substrate solutions (2-5
mM) were prepared in 30% (v/v)
N,N-dimethylformamide and diluted to 0.5 mM with 50 mM Hepes buffer, pH
7.4.
Enzyme Assays--
Experimental conditions were optimized for
each enzyme, taking into account the great propensity of dilute
solutions to stick to plastic and glass surfaces. Assays were carried
out at 37 °C in 50 mM Hepes buffer, pH 7.4, 0.75 M NaCl, 0.05% Igepal CA-630 (v/v) for HNE and Pr3 and in
50 mM Hepes buffer, pH 7.4, 0.1 M NaCl, 0.01%
Igepal CA-630 (v/v) for cathepsin G. The hydrolysis of
Abz-peptidyl-EDDnp substrates was followed by measuring the fluorescence at
ex = 320 nm and
em = 420 nm in a Hitachi F-2000 spectrofluorometer. The system was standardized
using Abz-FR-OH prepared from the total tryptic hydrolysis of an
Abz-FR-pNA solution; its concentration was determined from
the absorbance at 410 nm assuming
410 nm = 8,800 M
1 cm
1 for
p-nitroanilide. The concentrations of Abz-peptidyl-EDDnp substrate were determined by measuring the absorbance at 365 nm using
365 nm = 17,300 M
1 cm
1 for EDDnp.
Specificity constants
(kcat/Km) were determined
under first-order conditions using a substrate concentration far below
the Km (1-8 µM depending on the
enzyme). Final enzyme concentrations were 10-50 nM for HNE
and Pr3. Under these conditions, the Michaelis-Menten equation is
reduced to v = kobs · S where
kobs = Vm/Km. Integrating this equation over time gives ln[S] =
kobs · t + ln[S]o with [S]o and [S] being the
substrate concentrations at time 0 and time t,
respectively. Because Vm = kcat · [E]t where [E]t is the
final enzyme concentration, dividing kobs by
[E]t gave the
kcat/Km ratio. The
kobs for the first-order substrate hydrolysis
was calculated by fitting experimental data to the first-order law
using Enzfitter software (Elsevier Science Publishers, Amsterdam).
HNE and Pr3 were titrated with
1-PI, the titer of which had been
determined using bovine trypsin titrated with
p-nitrophenyl-p'-guanidinobenzoate (20).
Cathepsin G was titrated with
1-antichymotrypsin (21).
The Km for the hydrolysis of Abz-peptidyl-EDDnp
substrates by HNE and Pr3 was too high (>10 µM) to be
determined by measuring the rates of hydrolysis at different substrate
concentrations and fitting the to hyperbolic Michaelis-Menten rate
equation. Therefore, we used two competing substrates whose hydrolysis
products could be measured independently. Each substrate acts as a
competitive inhibitor of the other under these mixed alternative
substrates conditions. Km(obs) values of
intramolecularly quenched fluorogenic substrates were obtained by
measuring the dissociation constant (Ki) toward a
chromogenic paranitroanilide substrate. Assays were carried out by
adding 10 nM HNE or Pr3 to a mixture of 0.1-1
mM MeO-Suc-AAPV-pNA whose Km
are 0.085 (22) and 0.6 mM,2
respectively, and 0-100 µM fluorogenic
Abz-peptidyl-EDDnp derivative. The hydrolysis of
MeO-Suc-AAPV-pNA was monitored at 410 nm with <5% of
substrate hydrolyzed. The velocity of the enzyme action is described by
the following equation:
|
(Eq. 1)
|
with vi being the initial velocity at a given
substrate concentration with Abz-peptidyl-EDDnp competitor,
vo being the initial velocity at the same substrate
concentration without competitor, Km being the
Michaelis-Menten constant of the substrate, [S] being the chromogenic
substrate concentration, and [I] being the Abz-peptidyl-EDDnp
substrate concentration. The Ki value corresponds to
the observed Michaelis-Menten constant
(Km(obs)) of Abz-peptidyl-EDDnp
substrate as competitor.
Oxidation of Abz-peptidyl Substrates--
The methionyl residues
in Abz-peptidyl-EDDnp substrates were selectively oxidized to methionyl
sulfoxide with N-chlorosuccinimide (23). The peptides (30 nmol) were incubated with a 5-10-fold molar excess of aqueous
N-chlorosuccinimide in 0.1 M Tris-HCl buffer, pH
8.5, for 20 min at room temperature. Unreacted
N-chlorosuccinimide was removed by HPLC on a C18 cartridge
(2.1 × 30 mm, Brownlee, or 2 × 33 mm, Uptisphere) at a flow
rate of 0.3 ml/min with a linear gradient (0-60%, v/v) of
acetonitrile in 0.01% trifluoroacetic acid over 20 min.
Enzyme Activity at the Surface of PMN--
PMNs (5 × 103 to 5 × 104) were incubated in 50 mM Hepes buffer, pH 7.4, 150 mM NaCl, 0.05%
Igepal CA-630 (v/v) with 5 µM Abz-peptidyl-EDDnp substrate in microplate wells at 37 °C. The fluorescence was
recorded continuously using a microplate fluorescence reader (Spectra
Max Gemini, Molecular Devices) under continuous stirring. The enzyme activity in supernatants obtained by washing PMNs in PBS was also assayed. The elastase inhibitor EPI-HNE4 developed by Debiopharm S.A.
(Lausanne, Switzerland) was used at a final concentration of 0.1 µM and incubated for 15 min at 37 °C with
~104 cells before measuring residual elastase activity.
Peptidyl-CMK inhibitors (2 mM stock solution in 30%
N,N-dimethylformamide) were used at a final
concentration of 10
4 to 5 × 10
4
M and incubated for 60 or 120 min with ~104
M neutrophils or purified 10
9 M
HNE.
Chromatography and Analysis of Peptide Products--
Fluorogenic
substrates (4-8 µM final) were incubated with HNE or Pr3
(10-100 nM) at 37 °C in reaction buffer. The reaction was stopped by adding 4 volumes of absolute ethanol and incubating for
15 min on ice. Precipitated protein was removed by centrifugation at
13,000 × g for 10 min. The supernatant containing the
hydrolysis products was dried under vacuum and dissolved in 200 µl of
0.01% trifluoroacetic acid (v/v). Hydrolysis fragments were purified by reverse-phase chromatography on a C18 column (2.1 × 30 mm, Brownlee, or 2 × 33 mm, Uptisphere) using ThermoSeparation
product P200 pump and a Spectrasystem UV3000 detector (ThermoSeparation product) at a flow rate of 0.3 ml/min with a linear gradient (0-60%, v/v) of acetonitrile in 0.01% trifluoroacetic acid over 20 min. Eluted
peaks were monitored at three wavelengths (220, 320, and 360 nm)
simultaneously, which allowed the direct identification of
EDDnp-containing peptides prior to sequencing. Cleavage sites were
identified by N-terminal sequencing using an Applied Biosystems 477A
pulsed liquid sequencer with the chemicals and program recommended by
the manufacturer. Phenylthiohydantoin derivatives were identified with
an on-line model 120A analyzer.
 |
RESULTS |
Inhibitory Serpin-derived Substrates for HNE and Pr3--
At least
two serpin inhibitors,
1-PI (serpin A1) and MNEI (serpin B1), are
potent inhibitors of HNE and Pr3.
1-PI is the main extracellular
inhibitor of HNE in the lung (24). Its deficiency or inactivation by
proteolytic cleavage or oxidation is clearly associated with the
pathogenicity of several inflammatory lung diseases including emphysema
(25, 26). MNEI is an elastase inhibitor first found in the cytosol of
human lung macrophages and blood monocytes (27). It has since been
identified as a serpin inhibitor of elastase-like and chymotrypsin-like
proteases with two cleavage sites at Cys344 residue and at
the adjacent Phe343 residue in its RSL (28-30). We first
used fluorogenic peptides of different lengths derived from the RSL of
these two inhibitors as substrates for HNE and Pr3 for measuring
specificity constants (kcat/Km) (Fig.
1).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 1.
Peptide sequences derived from serpin RSLs
and used to prepare intramolecularly quenched fluorescent
substrates. Selected sequences are boxed.
Underlined residues were removed for the shorter substrates.
The P1-P1' cleavage sites in the parent serpin are in
bold.
|
|
1-PI-derived substrates were rapidly cleaved by HNE and
Pr3 and to a lesser extent by cathepsin G (Table
I). However, the kcat/Km for HNE was
approximately one order of magnitude greater than that for Pr3,
although the cleavage site was the same (Met-Ser bond) and identical to
that in the RSL of the parent serpin.
1-PI-derived substrates that
differ by the length of their peptide segments on the prime side had
similar kcat/Km values
regardless of the protease used with the exception of Pr3, which
preferentially cleaved the shorter substrate (Table I). This
observation suggests that residues beyond P3' have little influence on
the interaction between these proteases and their substrates.
View this table:
[in this window]
[in a new window]
|
Table I
Specificity constants kcat/Km for the hydrolysis of
fluorogenic substrates derived from the 1-PI and
MNEI-reactive site loop by neutral serine proteases from PMN
primary granules
n.s.h., no significant hydrolysis; n.d., not determined.
|
|
It was recently shown that MNEI uses either a Cys residue or a Phe
residue at P1 in its reactive center loop (30). We prepared two
substrates from the RSL of MNEI, one being shortened on both sides of
the peptidyl chain (Table I). HNE and Pr3 cleaved both substrates at
the same C-M bond as in the parent molecule, although the shorter
substrate, Abz-TFCMLQ-EDDnp, was hydrolyzed more slowly. However,
Abz-TFCMLQ-EDDnp is the first sensitive substrate to be reported that
is cleaved more efficiently by Pr3 than by HNE. Cathepsin G also
cleaves MNEI-derived substrates but at the F-C bond in agreement with
its substrate specificity. However, Abz-GIATFCMLMPEQ-EDDnp is cleaved
more efficiently than Abz-TFCMLQ-EDDnp (Table I). It is possible that
the sensitive bond within the shorter substrate is too close to the N
terminus to allow efficient cleavage by cathepsin G (16).
The oxidation of Met358 in the RSL of
1-PI reduced its
capacity to inactivate HNE ~2,000-fold (31). This phenomenon probably contributes to the protease-inhibitor imbalance at inflammatory sites
where neutrophils release reactive forms of oxygen (3). We looked at
the effects of oxidizing the Met residues in
1-PI and MNEI-derived
substrates, which have a Met residue at P1 and P1', respectively, on
the hydrolysis by HNE and Pr3. The hydrolysis of
1-PI-derived and
MNEI-derived substrates was dramatically altered when they were
oxidized with N-chlorosuccinimide. The kcat/Km values were reduced
by more than one order of magnitude (Table I). This finding suggests
that the oxidative microenvironment at inflammatory sites also
inactivates MNEI when this inhibitor is present locally. Adding native
(unoxidized) substrate to the reaction mixture restored full activity,
demonstrating that the trace amounts of N-chlorosuccinimide
remaining in the oxidized substrate after HPLC did not interfere with
the rate of hydrolysis.
A Selective Substrate for Pr3--
Several intracellular serpins
in addition to MNEI have a Cys residue in their RSL, which makes them
putative targets for HNE and Pr3. PI9 is found in the lung and other
tissues and is reported to be a potent inhibitor of HNE that uses a
cysteinyl residue at its reactive site (32). PI9 also inhibits granzyme
B (33) and caspase1 (34) but uses a different site in its RSL for this purpose. The predicted reactive site in CrmA, a closely related viral
homologue of PI9 that also inhibits caspase 1 and granzyme B, is an Asp
or a Cys, even though the Asp residue is most certainly involved in the
inhibition of these proteases (35, 36). A Cys residue is also present
in the RSL of the intracellular serpin inhibitor PI6, which is found in
monocytes and granulocytes, and is a potent inhibitor of cathepsin G
(37).
The hydrolysis of fluorogenic substrates covering the RSL of PI9
(Abz-VAECCQ-EDDnp), PI6 (Abz-MMRCAQ-EDDnp), and CrmA (Abz-VADCAQ-EDDnp) by HNE, Pr3 and cathepsin G were monitored. Cathepsin G did not cleave
any of these substrates. The PI9-derived substrate was cleaved very
efficiently by HNE and Pr3 (Table II) but
HNE cleaved at the C-Q bond, whereas Pr3 cleaved at the C-C bond.
Nevertheless, the specificity constants were similar (Table II). The
PI6-derived substrate was preferentially cleaved by Pr3 with a single
cleavage site at the C-A bond, but HNE also caused significant
hydrolysis at the A-Q bond; the ratio
kcat/Km(Pr3):kcat/Km(HNE) was ~2.8 (Table II). The CrmA-derived substrate, Abz-VADCAQ-EDDnp, which also has the Cys-Ala pair in its reactive loop, was cleaved very
efficiently by Pr3 but significantly more slowly by HNE (Table II). The
ratio
kcat/Km(Pr3)/kcat/Km(HNE)
was ~30. The difference depended mainly on
kcat values, because the Km
values are similar (Table III).
The difference in kcat/Km ratio is high enough to selectively measure Pr3 activity in a biological sample containing similar concentrations of HNE and Pr3.
View this table:
[in this window]
[in a new window]
|
Table II
Specificity constants kcat/Km for the hydrolysis of
fluorogenic substrates derived from the PI9, PI6, and CrmA-reactive
site loop by neutral serine proteases from PMN primary granules
n.s.h., no significant hydrolysis.
|
|
View this table:
[in this window]
[in a new window]
|
Table III
Michaelis-Menten constants for the hydrolysis of fluorogenic substrates
derived from the PAI-1 and CrmA-reactive site loop by neutral serine
proteases from PMN primary granules
|
|
A Selective Substrate for HNE--
PAI-1 is a member
of the serpin family involved in the regulation of fibrinolysis (38).
It is cleaved at a P1 = Arg residue in its RSL upon interaction
with urokinase-type and tissue-type plasminogen activators (39). It is
also cleaved and inactivated by HNE. The cleavage site was identified
as the P4-P3 (V-S) bond in intact PAI-1 (40). The substrate covering
the PAI-1 RSL from P5 to P10' (Abz-IVSARMAPEEIIMDRQ-EDDnp) was rapidly
hydrolyzed by HNE at the two Ile residues close to the C terminus but
also by Pr3 at the A-R bond at the N-terminal end. There was no
cleavage at the V-S bond as in the native serpin (40). The
kcat/Km values for the two
proteases were similar in the 105
M
1s
1 range (Table
IV). A shorter substrate, in which the
N-terminal peptide sequence containing the Pr3 cleavage site and one
Ile residue were deleted (Abz-APEEIMDRQ-EDDnp), was cleaved at a single Ile site by HNE. Unexpectedly, Pr3 also cleaved at the same site to
some extent. However, the
kcat/Km for HNE was 50-fold higher than that for Pr3, which allows almost selective measurement of
HNE activity, even in the presence of Pr3. The specificity constant is
also higher than that for the currently used HNE substrates MeO-Suc-AAPV-pNA
(kcat/Km = 182,000 M
1s
1 (41) and MeO-Suc-AAPV-AFC
(kcat/Km = 139,000 ± 18,000 M
1s
1 as determined in
this study.
View this table:
[in this window]
[in a new window]
|
Table IV
Specificity constants kcat/Km for the hydrolysis of
fluorogenic substrates derived from the PAI-1-reactive site loop by
neutral serine proteases from PMN primary granules
n.s.h., no significant hydrolysis; n.d., not determined.
|
|
The Km values for HNE and Pr3 on Abz-APEEIMDRQ-EDDnp
were determined by competition experiments using
MeO-Suc-AAPV-pNA as a competing substrate. Under these
conditions, the experimental Ki value corresponds to
the Km for Abz-APEEIMDRQ-EDDnp and was ~12-fold
higher for Pr3 than for HNE (Table III). Thus, both
Km and kcat contribute to
make the specificity constant for Pr3 less than that for HNE. The
oxidation of the P1' Met residue in Abz-APEEIMDRQ-EDDnp resulted in a
6.1-fold decrease in the specificity constant for HNE and a 9.1-fold
decrease in that for Pr3 (Table IV). The Abz-VSARQ-EDDnp substrate,
which includes both the HNE cleavage site in native PAI-1 (Val-Ser)
(40) and the Pr3 cleavage site in the longer PAI-1-derived substrate
described above (Ala-Arg), was not cleaved at a significant rate
by HNE or Pr3 (Table IV).
Measurement of HNE and Pr3 Activities at the Surface of
PMNs--
Part of the neutral proteases released from activated PMNs
remains bound to the cell membrane. This is an important form of active
proteases, because these enzymes are more resistant to inhibition by
local protease inhibitors (1, 2). Cell attachment of proteases
amplifies tissue injury by extending the time and efficiency of
uncontrolled proteolysis (reviewed in Ref. 3). The relative
contributions of HNE and Pr3 to this membrane-bound proteolytic
activity have not been investigated to date, because no substrate that
discriminates between these proteases when they are both present in a
solution has been available. Campbell et al. (1) attempted
to overcome this problem by studying the catalytic activity of
exogenous Pr3 bound to unstimulated cells. We used Abz-VADCAQ-EDDnp and
Abz-APEEIMDRQ-EDDnp to measure proteolytic activity at the surface of
purified blood neutrophils that had undergone minimal activation during
purification as judged from the low percentage of cells (<5%)
expressing CD63 by flow cytometry. Both substrates were rapidly
hydrolyzed by suspensions of freshly prepared neutrophils,
demonstrating that the two proteases are present and catalytically
active at their surface. Only a weak activation was observed when cells
were diluted to ~103 cells/µl and kept at 6 °C under
gentle stirring, and <15% cells expressed CD63 after overnight
storage in these conditions. However, keeping undiluted purified
neutrophils on ice for 3 h (>104 cells/µl) resulted
in the activation of 10-40% of the neutrophil population as deduced
from surface CD63. There was a parallel increase in proteolytic
activity on both substrates, indicating greater HNE and Pr3 expression
at the membrane surface of partially activated neutrophils. Proteolytic
activity remained after the cells were washed with PBS, centrifuged,
and suspended in the reaction buffer, whereas there was no significant
activity in the supernatant of freshly prepared or diluted stock cell
suspensions. Approximately 5% of the total activity can be released
into the supernatant of partially activated cells. HPLC analysis of the soluble fraction from cells incubated with Abz-VADCAQ-EDDnp and Abz-APEEIMDRQ-EDDnp showed that both substrates were cleaved at a
single site identical to those of Pr3 and HNE (Fig.
2). This finding indicates that HNE is
the main protease cleaving Abz-APEEIMDRQ-EDDnp and Pr3 is the main
protease cleaving Abz-VADCAQ-EDDnp. This hypothesis was reinforced by
the observation that the Abz-VADCAQ-EDDnp-hydrolyzing activity was
released more rapidly than that cleaving Abz-APEEIMDRQ-EDDnp from
freshly prepared cells washed with buffer containing 1.5 M
NaCl for 10 min at 37 °C (Fig. 3).
This finding is in agreement with the fact that Pr3 has a more acidic
pI and is therefore released more readily from the cell surface
than is HNE (1). Further confirmation was provided using the low
Mr specific inhibitor of HNE, EPI-HNE4,
developed by Debiopharm S.A. that inhibits both free and
membrane-bound HNE.3 EPI-HNE4
specifically and totally inhibits Abz-APEEIMDRQ-EDDnp-hydrolyzing activity but not Abz-VADCAQ-EDDnp-hydrolyzing activity when incubated at a final concentration of 0.1 µM with 104
neutrophils. By comparison, the peptidyl-chloromethylketone elastase and Pr3 inhibitor MeO-Suc-AAPA-CMK totally inhibited membrane-bound proteolytic activity on both Abz-APEEIMDRQ-EDDnp and Abz-VADCAQ-EDDnp, whereas the chymotrypsin-like Z-GLF-CMK inhibitor had no effect on
Abz-VADCAQ-EDDnp-cleaving activity and inhibited ~20% of the Abz-APEEIMDRQ-EDDnp-hydrolyzing activity under the experimental conditions used. Because of the possible release of oxidants from neutrophils, we checked that the methionyl residue in
Abz-APEEIMDRQ-EDDnp was not oxidized during the reaction, thus reducing
significantly its rate of hydrolysis (Table IV). This analysis
was done by comparing the HPLC elution times of the substrate and its
hydrolysis products upon hydrolysis by membrane-bound proteases with
that of Abz-APEEIM(O)DRQ-EDDnp, which is eluted earlier than the native
substrate. No peak eluting with the retention times of
Abz-APEEIM(O)DRQ-EDDnp or its hydrolysis product M (O)DRQ-EDDnp was
observed (data not shown).

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 2.
Identification of the cleavage sites within
Abz-APEEIMDRQ-EDDnp and Abz-VADCAQ-EDDnp after hydrolysis by free HNE
and Pr3 and purified PMNs. Reverse-phase HPLC chromatograms (220 nm) of 5 µM Abz-VADCAQ-EDDnp (no enzyme) (A),
5 µM Abz-VADCAQ-EDDnp + HNE (3 nM final)
(B), 5 µM Abz-VADCAQ-EDDnp + Pr3 (3 nM final) (C), 5 µM
Abz-VADCAQ-EDDnp + 2 × 104 purified neutrophils
(D), 5 µM Abz-APEEIMDRQ-EDDnp (no enzyme)
(A'), 5 µM Abz-APEEIMDRQ-EDDnp + HNE (3 nM final) (B'), 5 µM
Abz-APEEIMDRQ-EDDnp + Pr3 (3 nM final) (C'), and
5 µM Abz-APEEIMDRQ-EDDnp + 6 × 103
purified neutrophils (D'). The peak eluting at 16 min in
D and D' corresponds to an unprecipitated peptide
released from cells as deduced from HPLC of the cell supernatant after
ethanol precipitation (data not shown). The cleavage sites were
identified by sequencing the N termini of EDDnp-containing fragments
having an absorbance peak at 360 nm.
|
|

View larger version (49K):
[in this window]
[in a new window]
|
Fig. 3.
Measurement of HNE, Pr3, and cathepsin G
activities at the surface of purified neutrophils incubated with
NaCl. Cell suspensions were incubated for 10 min at 37 °C in
PBS, PBS+ 1 M NaCl, and PBS + 1.5 M NaCl,
centrifuged at 2,000 × g for 5 min, washed, and
resuspended in PBS. Cells were assayed for the hydrolysis of
Abz-APEEIMDRQ-EDDnp by HNE, Abz-VADCAQ-EDDnp by Pr3, and
Abz-TPFSGQ-EDDnp by cathepsin G.
|
|
Suspensions containing 5 × 103 to 5 × 104 cells/200 µl were enough to observe significant
hydrolysis within minutes because of the great sensitivity of these two
substrates. We calculated that membrane-bound HNE and Pr3 were present
at similar concentrations of 0.05-0.5 pg/cell (mean value 0.29 pg/cell, n = 13 experiments) using titrated HNE and Pr3
as standards. Similar values were found for cathepsin G at the cell
surface.4
An overall serine protease activity can also be measured using as few
as 1,000 cells and the nonspecific MNEI-derived substrate, Abz-GIATFCMLMPEQ-EDDnp, that is cleaved by HNE, Pr3, and cathepsin G
with specificity constants that are all greater than 2 × 105 M
1 s
1. However,
protease activity could not be quantified under these conditions
because of differences in the kinetic parameters for each protease.
 |
DISCUSSION |
Elastase, proteinase 3, and cathepsin G are all released from the
primary granules of activated PMNs when they are recruited and
activated at an inflammatory site and probably act in concert at this
site. The fate of each protease may differ depending on how they are
partitioned between soluble and membrane-attached forms and on their
sensitivity to inhibitors or other local controlling agents. The role
of each neutral protease from PMN primary granules has not been yet
elucidated because there is no substrate that allows the specific
measurement of each one, especially at the cell surface or in a complex
medium. For example, the currently used Pr3 substrate Boc-AANva-SBzl is
hydrolyzed nine times faster by HNE (8), which makes it impossible to
measure Pr3 activity in the presence of HNE. Furthermore, using
peptidyl-SBzl substrates requires a coupled assay with a thioldisulfide
reagent that may react with any reactive SH groups present
(e.g. at the cell surface) and interfere with the colored
reaction. Sensitive cathepsin G substrates that provide an alternative
to the use of peptidyl-SBzl substrates have only recently become
available (16).4 The catalytic activity of Pr3 bound
to the membranes of PMN or in the sputum of patients with cystic
fibrosis has been studied using indirect methods. They were based on
the susceptibility of Pr3 to protein inhibitors, especially secretory
leukocyte protease inhibitor (42), or on the use of exogenous Pr3 bound
to unstimulated neutrophils (1). HNE and Pr3 are structurally and
functionally very similar. Both cleave at small aliphatic amino acid
residues such as Val, Ala, and Ser at P1, but HNE also accommodates Cys and Leu residues at that position (9, 43). Both proteases also cleave
Met residue at P1, a feature shared by cathepsin G (44), which explains
why all three proteases are inhibited by
1-PI. HNE and PR3 have an
extended site of interaction with their substrate that extends from S4
to S3' as first suggested for HNE by Lestienne and Bieth (45) and later
shown by x-ray crystallography (14, 46). New substrates of greater
specificity for these proteases can be developed by investigating their
P' specificity. We used serpin RSLs because they are mobile and
flexible segments that are easily cleaved; however, they interact with
the target protease. Serpins may interact with target enzymes to form
an almost irreversible SDS-resistant complex or to inactivate the inhibitor by cleavage of its RSL without further binding to the protease. Some serpins that do not inhibit a given protease may also be
used as a substrate for this protease, thus making them inefficient for
their target enzyme. Therefore, separate residues in RSLs can be used
to broaden the inhibitory specificity (32, 47) or to inactivate the
serpin by proteolytic attack.
Substrates related to a serpin reactive site were first developed
by Nakajima et al. (44) using the reactive loop of
1-PI as substrates for HNE and cathepsin G. But these chromogenic
p-nitroanilide substrates were not suitable for
investigating the P' side of the cleavage site despite the importance
of S' subsites in substrate binding by these proteases. Since then, we
have developed substrates with intramolecularly quenched fluorescence,
some of which are based on the reactive loop of serpin inhibitors and
are more sensitive and specific than currently used fluorogenic or
chromogenic substrates (16, 48).
We first used sequences derived from the reactive loop of
1-PI and
MNEI, because both serpins inhibit HNE, Pr3, and to a lesser extent
cathepsin G. These substrates are all cleaved by the three neutral
proteases from PMN primary granules but at different rates. The
MNEI-derived substrate is cleaved more rapidly by Pr3 unlike currently
used Pr3 substrates, which are all better cleaved by HNE. The cleavage
sites are identical at a P1 Cys residue for the two proteases as in the
parent molecule (28, 29). Oxidation of the methionyl residue at P1 or
at P1' in these substrates considerably slowed the rate of degradation
regardless of the substrate or the protease used, which demonstrates
the importance of the P1' residue and agrees with the decreased
capability of oxidized serpins to inhibit elastase-like proteases
(49).
The RSL of the ov-serpins PI6 and PI9 and their viral homologue
CrmA all contain a Cys residue as does MNEI. PI9 is an intracellular serpin of the ovalbumin family that is found mainly in the lung and
placenta. It was first reported as an inhibitor of caspase 1 and
granzyme B (33, 34, 50) and later found to inhibit HNE through cleavage
at a Cys site (32). The PI9-derived substrate is cleaved by both HNE
and Pr3 but at different sites. PI6 has not yet been reported to be an
elastase inhibitor but has been shown to be a cathepsin G inhibitor
(37). Its RSL-derived substrate is preferentially cleaved by Pr3 again
at a Cys residue. Whether this cleavage occurs in the native serpin,
thus preventing it from inhibiting cathepsin G, remains to be
investigated. The viral serpin CrmA functions very similar to PI9; it
inhibits caspase 1 and granzyme B using a characteristic Asp residue at
P1 (35, 36). Cowpox virus uses this serpin to prevent the proteolytic activation of the proinflammatory cytokine interleukin-1
, thus facilitating viral infection (35). The CrmA RSL-derived substrate is
cleaved 30-times faster by Pr3 than by HNE, which makes it a
discriminating substrate for measuring Pr3 activity, even in the
presence of HNE. Pr3 also activates the precursor of interleukin-1
, representing an alternative pathway for the production of
proinflammatory cytokines, particularly in the context of local
inflammatory processes (5, 12).
PAI-1 is a potent inhibitor of fibrinolysis that can be inactivated by
HNE, thus providing a way to enhance fibrinolysis (40). We measured the
suitability of its RSL as a substrate for the neutral proteases of PMN
primary granules. There was no cleavage at the site reported for the
parent molecule, possibly because it lies close to the N terminus.
Nevertheless, HNE and Pr3 cleave this substrate efficiently but at
different sites. The quite different locations of these cleavage sites
made it possible to remove the cleavage site by Pr3 while
preserving the site for HNE. The resulting substrate was even more
sensitive to HNE than the substrate, perhaps because one of the
two neighboring Ile residues in the parent substrate had been removed
(Table IV). However, Pr3 also cleaved it to some extent at the HNE
site. This new Pr3 site was not identified in the initial PAI-1
substrate, which further emphasizes the similarity of these two
proteases. The difference in specificity constants was large enough,
however, to define experimental conditions for the almost specific
measurement of HNE, and the same was true for Pr3 using the
CrmA-derived substrate. This finding was confirmed using purified
neutrophils in which both HNE and Pr3 are present at the membrane
surface and can be measured selectively.
Abz-APEEIMDRQ-EDDnp-hydrolyzing activity was inhibited by a specific
inhibitor of HNE without altering Abz-VADCAQ-EDDnp-hydrolyzing
activity. Furthermore, Abz-VADCAQ-EDDnp-hydrolyzing activity was
released more rapidly from the surface of cells incubated with 1.5 M NaCl than was hydrolyzing activity cleaving
Abz-APEEIMDRQ-EDDnp. This finding agrees with a previous observation
that Pr3 is released more rapidly from the surface of neutrophils
because its pI is lower than that of HNE and cathepsin G (1). Campbell,
et al. (1) reached this conclusion by measuring
immunoreactive proteases in cell-free supernatants incubated overnight
at 4 °C. We confirmed this by measuring the residual activity of
each protease directly at the surface of neutrophils after they
had been incubated in 1.5 M NaCl.
We have also shown that similar amounts of HNE and Pr3 are
present at the surface of purified blood neutrophils that have undergone minimal activation during purification, and this is also true
for cathepsin G.4 Therefore, all three neutral
proteases from the primary granules of neutrophils are present in
similar concentrations at the cell surface where they remain active on
synthetic substrates and may act in concert at inflammatory sites to
which the neutrophils have been recruited.
There is now considerable evidence that the residual serine protease
activity in inflammatory fluids is attributed in large part to
proteases that are attached to PMN membranes and can escape from
inhibition by protein inhibitors (3). Measuring the activity of these
proteases selectively at the membrane surface will be of great help in
testing the activity of exogenous inhibitors developed to regulate
proteolytic activity at inflammatory sites where the protease/inhibitor
imbalance greatly influences the self-perpetuating inflammation
characteristic of chronic inflammatory diseases and especially airway inflammation.
 |
ACKNOWLEDGEMENTS |
We thank Dr. François Saudubray
(Debiopharm S.A., Lausanne, Switzerland) for providing the low
Mr elastase inhibitor, Catherine Girardin
for skillful technical assistance, and Owen Parkes for editing the
English text.
 |
FOOTNOTES |
*
This work was supported in France by Vaincre la
Mucoviscidose and Biotechnocentre and in Brazil by Fundação
de Amparo a Pesquisa do Estado de São Paulo and Conselho Nacional
de Desenvolvimento Científico e Tecnológico.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed. Tel.:
33-2-47-36-61-45; Fax: 33-2-47-36-60-46; E-mail:
gauthier@univ-tours.fr.
Published, JBC Papers in Press, July 11, 2002, DOI 10.1074/jbc.M202918200
2
J. Bieth, personal communication.
3
B. Korkmaz, S. Attucci, E. Hazouard, F. Saudubray, and F. Gauthier, unpublished results.
4
Attucci, S., Korkmaz, B., Juliano, L.,
Hazouard, E., Girardin, C., Brillard-Bourdet, M., Rehault, S.,
Anthonioz, P., and Gauthier, F. (2002) Biochem. J. 366, 965-970.
 |
ABBREVIATIONS |
The abbreviations used are:
HNE, human
neutrophil elastase;
Pr3, proteinase 3;
PMN, polymorphonuclear
leukocyte;
RSL, reactive site loop;
1-PI,
1-protease inhibitor;
FITC, fluorescein isothiocyanate;
PBS, phosphate-buffered saline;
MNEI, monocyte neutrophil elastase inhibitor;
Abz, ortho-aminobenzoic acid;
AFC, 7-amino-4-trifluoromethyl-coumarin;
Boc-AANva-SBzl, t-butyloxycarbonyl-Ala-Ala-Norvaline-thiobenzylester;
CMK, chloromethyl ketone;
CrmA, cytokine-response modifier A;
EDDnp, N-(2,4-dinitrophenyl)ethylenediamine;
HPLC, high performance
liquid chromatography;
PAI-1, plasminogen activator inhibitor 1;
MeO-Suc-, methoxysuccinyl.
 |
REFERENCES |
| 1.
|
Campbell, E. J.,
Campbell, M. A.,
and Owen, C. A.
(2000)
J. Immunol.
165,
3366-3374[Abstract/Free Full Text]
|
| 2.
|
Owen, C. A.,
Campbell, M. A.,
Sannes, P. L.,
Boukedes, S. S.,
and Campbell, E. J.
(1995)
J. Cell Biol.
131,
775-789[Abstract/Free Full Text]
|
| 3.
|
Owen, C. A.,
and Campbell, E. J.
(1999)
J. Leukocyte Biol.
65,
137-150[Abstract]
|
| 4.
|
Csernok, E.,
Ernst, M.,
Schmitt, W.,
Bainton, D. F.,
and Gross, W. L.
(1994)
Clin. Exp. Immunol.
95,
244-250[Medline]
[Order article via Infotrieve]
|
| 5.
|
Bank, U.,
and Ansorge, S.
(2001)
J. Leukocyte Biol.
69,
197-206[Abstract/Free Full Text]
|
| 6.
|
Evangelista, V.,
Rajtar, G.,
de Gaetano, G.,
White, J. G.,
and Cerletti, C.
(1991)
Blood
77,
2379-2388[Abstract/Free Full Text]
|
| 7.
|
Allen, D. H.,
and Tracy, P. B.
(1995)
J. Biol. Chem.
270,
1408-1415[Abstract/Free Full Text]
|
| 8.
|
Kam, C. M.,
Kerrigan, J. E.,
Dolman, K. M.,
Goldschmeding, R.,
Von dem Borne, A. E.,
and Powers, J. C.
(1992)
FEBS Lett.
297,
119-123[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Rao, N. V.,
Wehner, N. G.,
Marshall, B. C.,
Gray, W. R.,
Gray, B. H.,
and Hoidal, J. R.
(1991)
J. Biol. Chem.
266,
9540-9548[Abstract/Free Full Text]
|
| 10.
|
Duranton, J.,
Belorgey, D.,
Carrere, J.,
Donato, L.,
Moritz, T.,
and Bieth, J. G.
(2000)
FEBS Lett.
473,
154-156[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Robache-Gallea, S.,
Morand, V.,
Bruneau, J. M.,
Schoot, B.,
Tagat, E.,
Realo, E.,
Chouaib, S.,
and Roman-Roman, S.
(1995)
J. Biol. Chem.
270,
23688-23692[Abstract/Free Full Text]
|
| 12.
|
Coeshott, C.,
Ohnemus, C.,
Pilyavskaya, A.,
Ross, S.,
Wieczorek, M.,
Kroona, H.,
Leimer, A. H.,
and Cheronis, J.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
6261-6266[Abstract/Free Full Text]
|
| 13.
|
Ludemann, J.,
Utecht, B.,
and Gross, W. L.
(1990)
J. Exp. Med.
171,
357-362[Abstract/Free Full Text]
|
| 14.
|
Fujinaga, M.,
Chernaia, M. M.,
Halenbeck, R.,
Koths, K.,
and James, M. N.
(1996)
J. Mol. Biol.
261,
267-278[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Chagas, J. R.,
Juliano, L.,
and Prado, E. S.
(1991)
Anal. Biochem.
192,
419-425[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Réhault, S.,
Brillard-Bourdet, M.,
Juliano, M. A.,
Juliano, L.,
Gauthier, F.,
and Moreau, T.
(1999)
J. Biol. Chem.
274,
13810-13817[Abstract/Free Full Text]
|
| 17.
|
Schechter, I.,
and Berger, A.
(1967)
Biochem. Biophys. Res. Commun.
27,
157-162[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Oliveira, M. C.,
Hirata, I. Y.,
Chagas, J. R.,
Boschcov, P.,
Gomes, R. A.,
Figueiredo, A. F.,
and Juliano, L.
(1992)
Anal. Biochem.
203,
39-46[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Hirata, I. Y.,
Cezari, M. H. S.,
Nakaie, C. R.,
Boschcov, P.,
Ito, A. S.,
and Juliano, M. A.
(1994)
Lett. Pept. Sci.
1,
299-308
|
| 20.
|
Serveau, C.,
Moreau, T.,
Zhou, G. X., El-,
Moujahed, A.,
Chao, J.,
and Gauthier, F.
(1992)
FEBS Lett.
309,
405-408[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Ermolieff, J.,
Boudier, C.,
Laine, A.,
Meyer, B.,
and Bieth, J. G.
(1994)
J. Biol. Chem.
269,
29502-29508[Abstract/Free Full Text]
|
| 22.
|
Frommherz, K. J.,
Faller, B.,
and Bieth, J. G.
(1991)
J. Biol. Chem.
266,
15356-15362[Abstract/Free Full Text]
|
| 23.
|
Shechter, Y.,
Burstein, Y.,
and Patchornik, A.
(1975)
Biochemistry
14,
4497-4503[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
McElvaney, N. G.,
Hubbard, R. C.,
Birrer, P.,
Chernick, M. S.,
Caplan, D. B.,
Frank, M. M.,
and Crystal, R. G.
(1991)
Lancet
337,
392-394[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Tetley, T. D.
(1993)
Thorax
48,
560-565[Abstract]
|
| 26.
|
Eriksson, S.
(1996)
Chest
110 (Suppl. 6),
S237-S242[Medline]
[Order article via Infotrieve]
|
| 27.
|
Blondin, J.,
Rosenberg, R.,
and Janoff, A.
(1972)
Am. Rev. Respir. Dis.
106,
477-479[Medline]
[Order article via Infotrieve]
|
| 28.
|
Remold-O'Donnell, E.,
Chin, J.,
and Alberts, M.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
5635-5639[Abstract/Free Full Text]
|
| 29.
|
Sugimori, T.,
Cooley, J.,
Hoidal, J. R.,
and Remold-O'Donnell, E.
(1995)
Am. J. Respir. Cell Mol. Biol.
13,
314-322[Abstract]
|
| 30.
|
Cooley, J.,
Takayama, T. K.,
Shapiro, S. D.,
Schechter, N. M.,
and Remold-O'Donnell, E.
(2001)
Biochemistry
40,
15762-15770[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Hubbard, R.,
and Crystal, R.
(1991)
in
The Lung
(Crystal, R.
, and West, J., eds), Vol. 2
, pp. 1775-1787, Raven Press, Ltd., New York
|
| 32.
|
Dahlen, J. R.,
Foster, D. C.,
and Kisiel, W.
(1999)
Biochim. Biophys. Acta
1451,
233-241[Medline]
[Order article via Infotrieve]
|
| 33.
|
Sun, J.,
Bird, C. H.,
Sutton, V.,
McDonald, L.,
Coughlin, P. B., De,
Jong, T. A.,
Trapani, J. A.,
and Bird, P. I.
(1996)
J. Biol. Chem.
271,
27802-27809[Abstract/Free Full Text]
|
| 34.
|
Annand, R. R.,
Dahlen, J. R.,
Sprecher, C. A., De,
Dreu, P.,
Foster, D. C.,
Mankovich, J. A.,
Talanian, R. V.,
Kisiel, W.,
and Giegel, D. A.
(1999)
Biochem. J.
342,
655-665
|
| 35.
|
Ray, C. A.,
Black, R. A.,
Kronheim, S. R.,
Greenstreet, T. A.,
Sleath, P. R.,
Salvesen, G. S.,
and Pickup, D. J.
(1992)
Cell
69,
597-604[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Quan, L. T.,
Caputo, A.,
Bleackley, R. C.,
Pickup, D. J.,
and Salvesen, G. S.
(1995)
J. Biol. Chem.
270,
10377-10379[Abstract/Free Full Text]
|
| 37.
|
Scott, F. L.,
Hirst, C. E.,
Sun, J.,
Bird, C. H.,
Bottomley, S. P.,
and Bird, P. I.
(1999)
Blood
93,
2089-2097[Abstract/Free Full Text]
|
| 38.
|
Levin, E. G.,
and Santell, L.
(1987)
J. Cell Biol.
105,
2543-2549[Abstract/Free Full Text]
|
| 39.
|
Sherman, P. M.,
Lawrence, D. A.,
Yang, A. Y.,
Vandenberg, E. T.,
Paielli, D.,
Olson, S. T.,
Shore, J. D.,
and Ginsburg, D.
(1992)
J. Biol. Chem.
267,
7588-7595[Abstract/Free Full Text]
|
| 40.
|
Wu, K.,
Urano, T.,
Ihara, H.,
Takada, Y.,
Fujie, M.,
Shikimori, M.,
Hashimoto, K.,
and Takada, A.
(1995)
Blood
86,
1056-1061[Abstract/Free Full Text]
|
| 41.
|
Stein, R. L.,
Strimpler, A. M.,
Hori, H.,
and Powers, J. C.
(1987)
Biochemistry
26,
1301-1305[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Witko-Sarsat, V.,
Halbwachs-Mecarelli, L.,
Schuster, A.,
Nusbaum, P.,
Ueki, I.,
Canteloup, S.,
Lenoir, G.,
Descamps-Latscha, B.,
and Nadel, J. A.
(1999)
Am. J. Respir. Cell Mol. Biol.
20,
729-736[Abstract/Free Full Text]
|
| 43.
|
Blow, A. M.
(1977)
Biochem. J.
161,
13-16[Medline]
[Order article via Infotrieve]
|
| 44.
|
Nakajima, K.,
Powers, J. C.,
Ashe, B. M.,
and Zimmerman, M.
(1979)
J. Biol. Chem.
254,
4027-4032[Free Full Text]
|
| 45.
|
Lestienne, P.,
and Bieth, J. G.
(1980)
J. Biol. Chem.
255,
9289-9294[Free Full Text]
|
| 46.
|
Bode, W.,
Meyer, E., Jr.,
and Powers, J. C.
(1989)
Biochemistry
28,
1951-1963[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Dahlen, J. R.,
Foster, D. C.,
and Kisiel, W.
(1998)
Biochem. Biophys. Res. Commun.
244,
172-177[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Bourgeois, L.,
Brillard-Bourdet, M.,
Deperthes, D.,
Juliano, L.,
Tremblay, R.,
Dubé, J. Y.,
and Gauthier, F.
(1997)
J. Biol. Chem.
272,
29590-29595[Abstract/Free Full Text]
|
| 49.
|
Carp, H.,
and Janoff, A.
(1980)
J. Clin. Invest.
66,
987-995[Medline]
[Order article via Infotrieve]
|
| 50.
|
Young, J. L.,
Sukhova, G. K.,
Foster, D.,
Kisiel, W.,
Libby, P.,
and Schonbeck, U.
(2000)
J. Exp. Med.
191,
1535-1544[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
B. Korkmaz, E. Hajjar, T. Kalupov, N. Reuter, M. Brillard-Bourdet, T. Moreau, L. Juliano, and F. Gauthier
Influence of Charge Distribution at the Active Site Surface on the Substrate Specificity of Human Neutrophil Protease 3 and Elastase: A KINETIC AND MOLECULAR MODELING ANALYSIS
J. Biol. Chem.,
January 19, 2007;
282(3):
1989 - 1997.
[Abstract]
[Full Text]
[PDF]
|
 |
|